News
![](/upload/iblock/23d/23d2694e90ca35fd84dba3674731caae.jpg)
Press Center
![](/upload/resize_cache/iblock/dd4/140_80_2/dd4b48ba2ffa07c74d86fc41f702b6b7.png)
06.08.2018
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
More
Topics Petrovax Pharm